Q&A: Lon­za­'s Chris­t­ian Dowdeswell talks HPA­PIs and the Oas­mia deal

The mR­NA boom has been ben­e­fi­cial for CD­MOs, and Lon­za is no dif­fer­ent. It’s up­grad­ed three of its sites — two in Eu­rope and one in New Hamp­shire — since land­ing deals with Mod­er­na to pro­duce the biotech’s Covid-19 vac­cine, and is be­ing con­sid­ered one of the big­wigs that will be re­spon­si­ble for more than half of the world’s drug ca­pac­i­ty by 2025.

And last week, the Swiss drug­mak­er inched clos­er to that goal, when it an­nounced the com­ple­tion of a mas­sive up­grade at a Nan­sha, Chi­na man­u­fac­tur­ing site. The up­grade will ex­pand the com­pa­ny’s abil­i­ty to man­u­fac­ture high­ly po­tent ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, and a deal has al­ready been signed with Oas­mia Phar­ma­ceu­ti­cals to make its ovar­i­an can­cer drug can­di­date. That will start lat­er this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER